vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $196.0M, roughly 1.4× Axsome Therapeutics, Inc.). Astera Labs, Inc. runs the higher net margin — 16.6% vs -14.6%, a 31.2% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs 65.0%). Astera Labs, Inc. produced more free cash flow last quarter ($76.6M vs $-18.7M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 61.7%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ALAB vs AXSM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $196.0M |
| Net Profit | $45.0M | $-28.6M |
| Gross Margin | 75.6% | — |
| Operating Margin | 24.7% | -13.8% |
| Net Margin | 16.6% | -14.6% |
| Revenue YoY | 91.8% | 65.0% |
| Net Profit YoY | 82.0% | 61.9% |
| EPS (diluted) | $0.25 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $196.0M | ||
| Q3 25 | $230.6M | $171.0M | ||
| Q2 25 | $191.9M | $150.0M | ||
| Q1 25 | $159.4M | $121.5M | ||
| Q4 24 | $141.1M | $118.8M | ||
| Q3 24 | $113.1M | $104.8M | ||
| Q2 24 | $76.8M | $87.2M | ||
| Q1 24 | $65.3M | $75.0M |
| Q4 25 | $45.0M | $-28.6M | ||
| Q3 25 | $91.1M | $-47.2M | ||
| Q2 25 | $51.2M | $-48.0M | ||
| Q1 25 | $31.8M | $-59.4M | ||
| Q4 24 | $24.7M | $-74.9M | ||
| Q3 24 | $-7.6M | $-64.6M | ||
| Q2 24 | $-7.5M | $-79.3M | ||
| Q1 24 | $-93.0M | $-68.4M |
| Q4 25 | 75.6% | — | ||
| Q3 25 | 76.2% | — | ||
| Q2 25 | 75.8% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.0% | — | ||
| Q3 24 | 77.7% | — | ||
| Q2 24 | 77.9% | — | ||
| Q1 24 | 77.4% | — |
| Q4 25 | 24.7% | -13.8% | ||
| Q3 25 | 24.0% | -27.0% | ||
| Q2 25 | 20.7% | -24.5% | ||
| Q1 25 | 7.1% | -46.9% | ||
| Q4 24 | 0.1% | -61.1% | ||
| Q3 24 | -7.9% | -59.8% | ||
| Q2 24 | -31.7% | -89.5% | ||
| Q1 24 | -127.1% | -89.7% |
| Q4 25 | 16.6% | -14.6% | ||
| Q3 25 | 39.5% | -27.6% | ||
| Q2 25 | 26.7% | -32.0% | ||
| Q1 25 | 20.0% | -48.9% | ||
| Q4 24 | 17.5% | -63.1% | ||
| Q3 24 | -6.7% | -61.7% | ||
| Q2 24 | -9.8% | -91.0% | ||
| Q1 24 | -142.5% | -91.1% |
| Q4 25 | $0.25 | $-0.55 | ||
| Q3 25 | $0.50 | $-0.94 | ||
| Q2 25 | $0.29 | $-0.97 | ||
| Q1 25 | $0.18 | $-1.22 | ||
| Q4 24 | $1.23 | $-1.54 | ||
| Q3 24 | $-0.05 | $-1.34 | ||
| Q2 24 | $-0.05 | $-1.67 | ||
| Q1 24 | $-1.77 | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $322.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $88.3M |
| Total Assets | $1.5B | $689.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $322.9M | ||
| Q3 25 | $140.4M | $325.3M | ||
| Q2 25 | $162.3M | $303.0M | ||
| Q1 25 | $86.4M | $300.9M | ||
| Q4 24 | $79.6M | $315.4M | ||
| Q3 24 | $126.1M | $327.3M | ||
| Q2 24 | $421.1M | $315.7M | ||
| Q1 24 | $696.1M | $331.4M |
| Q4 25 | $1.4B | $88.3M | ||
| Q3 25 | $1.3B | $73.7M | ||
| Q2 25 | $1.1B | $73.1M | ||
| Q1 25 | $1.0B | $53.2M | ||
| Q4 24 | $964.8M | $57.0M | ||
| Q3 24 | $889.6M | $92.9M | ||
| Q2 24 | $845.3M | $102.9M | ||
| Q1 24 | $808.8M | $144.0M |
| Q4 25 | $1.5B | $689.8M | ||
| Q3 25 | $1.4B | $669.3M | ||
| Q2 25 | $1.3B | $639.8M | ||
| Q1 25 | $1.1B | $596.7M | ||
| Q4 24 | $1.1B | $568.5M | ||
| Q3 24 | $983.1M | $561.5M | ||
| Q2 24 | $915.5M | $548.2M | ||
| Q1 24 | $864.9M | $545.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $-18.7M |
| Free Cash FlowOCF − Capex | $76.6M | $-18.7M |
| FCF MarginFCF / Revenue | 28.3% | -9.6% |
| Capex IntensityCapex / Revenue | 6.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 2.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | $-93.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $-18.7M | ||
| Q3 25 | $78.2M | $1.0M | ||
| Q2 25 | $135.4M | $-32.4M | ||
| Q1 25 | $10.5M | $-43.4M | ||
| Q4 24 | $39.7M | $-26.2M | ||
| Q3 24 | $63.5M | $-18.6M | ||
| Q2 24 | $29.8M | $-30.1M | ||
| Q1 24 | $3.7M | $-53.5M |
| Q4 25 | $76.6M | $-18.7M | ||
| Q3 25 | $65.9M | $988.0K | ||
| Q2 25 | $133.3M | $-32.4M | ||
| Q1 25 | $6.0M | $-43.7M | ||
| Q4 24 | $24.3M | $-26.2M | ||
| Q3 24 | $46.8M | $-18.7M | ||
| Q2 24 | $28.5M | $-30.2M | ||
| Q1 24 | $228.0K | $-53.6M |
| Q4 25 | 28.3% | -9.6% | ||
| Q3 25 | 28.6% | 0.6% | ||
| Q2 25 | 69.5% | -21.6% | ||
| Q1 25 | 3.7% | -36.0% | ||
| Q4 24 | 17.2% | -22.1% | ||
| Q3 24 | 41.4% | -17.9% | ||
| Q2 24 | 37.1% | -34.6% | ||
| Q1 24 | 0.3% | -71.4% |
| Q4 25 | 6.9% | 0.0% | ||
| Q3 25 | 5.3% | 0.0% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 2.8% | 0.3% | ||
| Q4 24 | 10.9% | 0.0% | ||
| Q3 24 | 14.8% | 0.1% | ||
| Q2 24 | 1.7% | 0.1% | ||
| Q1 24 | 5.2% | 0.1% |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 2.64× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
